<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467907</url>
  </required_header>
  <id_info>
    <org_study_id>MO29594</org_study_id>
    <secondary_id>2014-005491-28</secondary_id>
    <nct_id>NCT02467907</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer</brief_title>
  <official_title>A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study is to assess safety as defined by the frequency and severity of gastrointestinal
      (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula in participants
      treated with bevacizumab 15 milligrams per kilogram (mg/kg) in combination with paclitaxel
      and carboplatin, all repeated every 3 weeks, for recurrent, persistent or metastatic cervical
      cancer. In addition, this study will include evaluation of the overall safety profile of
      bevacizumab in combination with paclitaxel and carboplatin in this setting, assessment of GI
      perforation/fistula, GI-vaginal fistula and GU fistula events over time, and evaluation of
      efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 28, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with GI Perforation/Fistula Events by Grade According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with GI-Vaginal Fistula Events by Grade According to NCI-CTCAE Version 4.0</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with GU Fistula Events by Grade According to NCI-CTCAE Version 4.0</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First GI Perforation/Fistula</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First GI-Vaginal Fistula</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First GU Fistula</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Intensity (Ratio of Actual Dose Administered Versus Intended Dose) for Bevacizumab During the Treatment Period</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Intensity (Ratio of Actual Dose Administered Versus Intended Dose) for Carboplatin During the Treatment Period</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Intensity (Ratio of Actual Dose Administered Versus Intended Dose) for Paclitaxel During the Treatment Period</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment for Bevacizumab</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment for Carboplatin</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment for Paclitaxel</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with AEs Leading to Treatment Interruption or Permanent discontinuation</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Deaths Causally Related to Treatment</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria for Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab in Combination with Carboplatin and Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks</description>
    <arm_group_label>Bevacizumab in Combination with Carboplatin and Paclitaxel</arm_group_label>
    <other_name>Avastin, RO4876646</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administration of carboplatin at 5 milligrams per milliliter*minute (mg/mL*min) on Day 1 every 3 weeks for at least 6 cycles</description>
    <arm_group_label>Bevacizumab in Combination with Carboplatin and Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m^2) on Day 1 every 3 weeks for at least 6 cycles</description>
    <arm_group_label>Bevacizumab in Combination with Carboplatin and Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Life expectancy greater than or equal to (&gt;=3) months

          -  For women who are not postmenopausal or surgically sterile, agreement to remain
             abstinent or use single or combined contraceptive methods that result in a failure
             rate of less than (&lt;) 1 percent (%) per year during the treatment period and for at
             least 6 months after the last dose of study drug

          -  Distant metastatic, recurrent or persistent squamous cell carcinoma, adenosquamous
             carcinoma or adenocarcinoma of the cervix that is not amenable to curative treatment
             with surgery and/or radiation therapy

          -  Either measurable or non-measurable disease. If disease is non-measurable or limited
             to the radiation field, a biopsy or fine-needle aspiration is required to confirm
             malignancy

          -  Eligible for carboplatin and paclitaxel chemotherapy in accordance with local
             standards of care

          -  Adequate hematological, renal and hepatic function

          -  Normal blood coagulation parameters

          -  Recovered (to Grade less than or equal to [&lt;=] 1) from the effects of prior surgery,
             radiation therapy or chemoradiotherapy

        Exclusion Criteria:

          -  Pregnant or lactating

          -  History of other malignancy within 5 years before screening, except for non-melanoma
             skin carcinoma

          -  Ongoing disease involving the bladder or rectum at screening/baseline. In participants
             with pelvic disease, absence of tumor in the bladder or rectal mucosa must be
             demonstrated by magnetic resonance imaging (MRI) (preferred method, or
             endoscopy/cystoscopy if MRI is not easily accessible) within 28 days before enrolment

          -  Evidence of abdominal free air

          -  Bilateral hydronephrosis

          -  Untreated central nervous system (CNS) metastases

          -  Prior chemotherapy for recurrent, persistent or metastatic cervical cancer. Prior
             adjuvant or neoadjuvant chemotherapy for Stage I-IVA disease (i.e. for non-metastatic
             disease) is permitted if completed greater than (&gt;) 6 months before first study dose

          -  Prior chemoradiation within the 3 months preceding first study dose

          -  Prior radiotherapy delivered using cobalt

          -  Prior or current bevacizumab or other anti-angiogenic treatment

          -  Requirement for treatment with any medicinal product that contraindicates the use of
             any of the study drugs, may interfere with the planned treatment, affects participant
             compliance or puts the participant at high risk for treatment-related complications

          -  Treatment with another investigational agent within 28 days or 2 investigational agent
             half-lives before first study dose

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             before the first dose of bevacizumab or anticipation of the need for major surgery
             during the course of study treatment

          -  Minor surgical procedure within 2 days before the first dose of study drug

          -  Any prior history of fistula or GI perforation

          -  Known hypersensitivity to bevacizumab or any of its excipients, Chinese hamster ovary
             cell products or other recombinant human or humanized antibodies to any planned
             chemotherapy

          -  Active GI bleeding or ulcer

          -  Uncontrolled hypertension

          -  Clinically significant active cardiovascular disease

          -  National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
             Version 4.0, Grade greater than or equal to (&gt;=) 2 peripheral vascular disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral (CORI)</name>
      <address>
        <city>La Rioja</city>
        <zip>F5300COE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFMG</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>31270-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologica Brasil S/S LTDA - EPP</name>
      <address>
        <city>Belem</city>
        <state>PA</state>
        <zip>66053-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer - INCa; Pesquisa Clinica</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo - ICESP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Oncological Center - Plovdiv, EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Nadezhda</name>
      <address>
        <city>Sofia</city>
        <zip>1330</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A.</name>
      <address>
        <city>Monteria</city>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncólogos de Occidente</name>
      <address>
        <city>Pereira</city>
        <zip>600004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica CIMCA</name>
      <address>
        <city>San Jose</city>
        <zip>10103</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse; Urologie Gynecologie</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Oncologie Medicale</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandras General Hospital of Athens; Oncology Department</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO</name>
      <address>
        <city>Athens</city>
        <zip>151 23</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio de Medicina Especializada Integra</name>
      <address>
        <city>Distrito Federal</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia; Oncology</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Estatal ISSEMYM</name>
      <address>
        <city>Toluca</city>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hemato Oncologico Paitilla</name>
      <address>
        <city>Panama City</city>
        <zip>0832</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Panamá</name>
      <address>
        <city>Panama</city>
        <zip>082400133</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bialostockie Centrum Onkologi</name>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. M.Sklodowskiej-Curie; Klinika Ginekologii Onkologicznej</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wielkopolskie Centrum Onkologii im. M. Sklodowskiej-Curie</name>
      <address>
        <city>Poznan</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut M.Sklodowskiej-Curie; Klinika Ginekologii Onkologicznej</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPO do Porto; Servico de Oncologia Medica</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie Sfantul Nectarie</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Institute of Oncology Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Oncology &amp; Gynecology; City Clinical Oncology Dispensary</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Onc/Rad Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Johannesberg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pretoria; Department of Medical Oncology</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals; Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson International Espana</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano Oncologia; Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Baskent University Medicine Faculty; Gynaecology</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Uni of Medicine Faculty; Oncology Dept</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

